CERVAVAC, India’s first indigenously developed gender-neutral quadrivalent Human Papillomavirus (HPV) vaccine manufactured by the Serum Institute of India (SII), has received World Health Organization (WHO) prequalification, marking a major milestone for India’s HPV vaccine programme and global immunisation efforts. The WHO prequalification became effective on

